You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Claims for Patent: 11,103,497

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,103,497

Title:	Treatment of imatinib resistant leukemia
Abstract:	The present invention provides 4-anilino-3-quinolinecarbonitriles compounds useful for treating a subject having an BcrAbl positive leukemia that is resistant to imatinib.
Inventor(s):	Hewes; Becker (Middlesex, MA)
Assignee:	Wyeth LLC (New York, NY)
Application Number:	12/129,935
Patent Claims:	1. A method for treating a BcrAbl positive leukemia in a subject that is resistant to imatinib which comprises administering to the subject a therapeutically effective amount of 4-[(2,4-Dichloro-5-methoxy-phenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piper- azinyl)propoxy]-3-quinolinecarbonitrile, wherein the subject has a mutation in BcrAbl protein at F317L. 2. A method for treating a BcrAbl positive leukemia in a subject that is resistant to imatinib which comprises administering to the subject a therapeutically effective amount of 4-[(2,4-Dichloro-5-methoxy-phenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piper- azinyl)propoxy]-3-quinolinecarbonitrile, wherein the subject has a resistance-associated nucleic acid mutation in the BcrAbl gene at 949T>C. 3. The method of claim 1, wherein the leukemia is Chronic Myelogenous Leukemia. 4. The method of claim 2, wherein the leukemia is Chronic Myelogenous Leukemia. 5. The method of claim 1, wherein the leukemia is Acute Lymphocytic Leukemia. 6. The method of claim 2, wherein the leukemia is Acute Lymphocytic Leukemia. 7. The method of claim 1, wherein the compounds are administered to the subject in combination with one or more other compounds used to treat a BcrAbl positive leukemia. 8. The method of claim 2, wherein the compounds are administered to the subject in combination with one or more other compounds used to treat a BcrAbl positive leukemia. 9. The method of claim 7, wherein the one or more other compounds includes imatinib. 10. The method of claim 8, wherein the one or more other compounds includes imatinib.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.